UIMF:F:F- (EUR)

ETF | Others |

Last Closing

USD 16.594

Change

-0.12 (-0.73)%

Market Cap

N/A

Volume

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-06 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 101.74B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.34 (-0.66%)

USD 101.37B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.03 (+0.05%)

USD 96.03B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.08 (-0.52%)

USD 57.02B
XJSE:F Xtrackers II - Japan Governmen..

-0.01 (-0.07%)

USD 53.72B
VUSA:F Vanguard Funds Public Limited ..

-1.20 (-1.25%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 45.80B
0ZC:F Zscaler Inc

+1.75 (+0.85%)

USD 37.92B
BSND:F Danone SA

-0.10 (-0.68%)

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

-1.06 (-0.85%)

USD 24.77B

ETFs Containing UIMF:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.78% 82% B 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.78% 82% B 73% C
Trailing 12 Months  
Capital Gain 6.41% 73% C 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.41% 70% C- 58% F
Trailing 5 Years  
Capital Gain 77.40% 74% C 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 77.40% 74% C 53% F
Average Annual (5 Year Horizon)  
Capital Gain 10.64% 72% C 67% D+
Dividend Return 10.64% 70% C- 59% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.90% 62% D 90% A-
Risk Adjusted Return 97.60% 89% A- 92% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike